ACTIVE_NOT_RECRUITING

Real-life-persistence to Antifibrotic Treatments

Real-life-Persistence to Antifibrotic Treatments

NCT06485635•Boehringer Ingelheim

Summary

This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment. Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All patients with a reimbursement of AF treatment between 2018 and 2022 will be included for analysis.

Locations (1)

Clinityx

Boulogne-Billancourt, France

Key Dates

Start Date

October 16, 2024

Primary Completion Date

March 31, 2026

Completion Date

March 31, 2026

Last Updated

February 24, 2026

Enrollment

10,646

ACTUAL participants

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

Nintedanib

DRUG

Pirfenidone

DRUG

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis

View study

RECRUITINGPHASE3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT07299695

Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECRUITINGNA